Search - tctmd.com

Displaying 781 - 800 of 849

Sort: Relevancy | Date

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

News Conference News

Novel Anticoagulants Showing Benefits in A-fib Subgroups

August 29, 2011

News Conference News

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

August 28, 2011

News Daily News

CT Perfusion Imaging Captures Anatomy, Function

Caitlin E. Cox

August 24, 2011

News Industry News

Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study

August 15, 2011

News Daily News

ROCKET AF Published: Rivaroxaban Matches Warfarin in Treating A-Fib Patients

Caitlin E. Cox

August 10, 2011

News Daily News

Finding CAD on Elective Angiography Varies Widely Among Hospitals

August 08, 2011

News Daily News

Details on Clopidogrel Discontinuation Remain Elusive, Unclear

L.A. McKeown

August 05, 2011

News Daily News

Interruption of Antiplatelet Therapy Unnecessary for Tooth Extraction

July 27, 2011

News Daily News

Delayed Primary PCI Generally Superior to Early Fibrinolysis for STEMI

July 25, 2011

News Daily News

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Jason Kahn

July 25, 2011

News Daily News

Ticagrelor Gains FDA Approval for Use in ACS

Caitlin E. Cox

July 22, 2011

News Daily News

Prior Medication Adherence Predicts Post-PCI Clopidogrel Compliance

July 20, 2011

News Industry News

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

July 20, 2011

News Daily News

PCI Feasible Even in CAD Patients with End-Stage Liver Disease

July 15, 2011

News Daily News

Bleeding in ACS Patients Takes Center Stage in ESC Position Paper

July 05, 2011

News Daily News

ARISTOTLE Makes Its Case: Apixaban Noninferior to Warfarin in A-fib

June 24, 2011

News Daily News

Renal Dysfunction Takes Toll on Carotid Revascularization Outcomes

June 22, 2011

News Daily News

No Advantage with Facilitated PCI Even in Patients Most Likely to Benefit

Jason Kahn

June 20, 2011

News Daily News

Study Finds All-Comers Design Not So All Inclusive

Caitlin E. Cox

June 15, 2011

Advertisement

Long-term Antiplatelet Therapy: All Risk, No Benefit

Novel Anticoagulants Showing Benefits in A-fib Subgroups

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

CT Perfusion Imaging Captures Anatomy, Function

Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study

ROCKET AF Published: Rivaroxaban Matches Warfarin in Treating A-Fib Patients

Finding CAD on Elective Angiography Varies Widely Among Hospitals

Details on Clopidogrel Discontinuation Remain Elusive, Unclear

Interruption of Antiplatelet Therapy Unnecessary for Tooth Extraction

Delayed Primary PCI Generally Superior to Early Fibrinolysis for STEMI

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Ticagrelor Gains FDA Approval for Use in ACS

Prior Medication Adherence Predicts Post-PCI Clopidogrel Compliance

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

PCI Feasible Even in CAD Patients with End-Stage Liver Disease

Bleeding in ACS Patients Takes Center Stage in ESC Position Paper

ARISTOTLE Makes Its Case: Apixaban Noninferior to Warfarin in A-fib

Renal Dysfunction Takes Toll on Carotid Revascularization Outcomes

No Advantage with Facilitated PCI Even in Patients Most Likely to Benefit

Study Finds All-Comers Design Not So All Inclusive

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content